Predictors and moderators of outcomes in mindfulness-based cognitive therapy intervention for early breast cancer patients

Noriko Tamura, C.PSY., M.A.1, Sunre Park, R.N., C.PSY., M.A.2, Yasunori Sato, PH.D.3, Yasuko Sato, R.N., M.H.SC.4, Yuka Takita, R.N., M.S.N.5, Akira Ninomiya, M.D.1,6, Mitsuhito Sado, M.D., M.SC., PH.D.1,6, Masaru Mimura, M.D., PH.D.1 and Daisuke Fujisawa, M.D., C.PSY., PH.D.1,7

1Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan; 2Faculty of Nursing and Medicine Care, Keio University, Shinjuku-ku, Tokyo, Japan; 3Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan; 4Department of Nursing, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan; 5Faculty of Health Sciences, Tokyo Kasei University, Itabashi-ku, Tokyo, Japan; 6Center for Stress Research, Keio University, Shinjuku-ku, Tokyo, Japan and 7Division of Patient Safety, Keio University Hospital, Shinjuku-ku, Tokyo, Japan

Abstract

Objectives. To deliver mindfulness-based cognitive therapy (MBCT) efficiently, the present study aimed (1) to identify predictors and moderators of patients who benefit from MBCT for psychological distress and (2) to explore the initial treatment reaction to identify the optimal number of sessions that produce a significant clinical effect.

Methods. This is the secondary analysis of a randomized controlled trial of MBCT for breast cancer patients (N = 74). We classified the participants into remitters vs. non-remitters, and responder vs. non-responders, according to the total score of the Hospital Anxiety and Depression Scale at the end of the intervention. We conducted multivariate analyses to explore predictors of response and remission. We adopted generalized estimating equations to explore the optimal number of sessions.

Results. Sociodemographic and clinical backgrounds did not have significant influence on the treatment outcomes of the MBCT. Better program adherence, which was represented as the participants’ better attendance to the MBCT program, was a significant predictor of both remission and response [odds ratio (OR) = 1.90, 95% confidence interval (CI) 1.25–2.69, p = 0.003, and OR = 1.72, 95% CI 1.12–2.65, p = 0.013, respectively]. It was not until seventh session that the remission rate exceeded 50% and the response rate showed significance.

Significance of results. Sociodemographic and clinical characteristics did not significantly influence the treatment outcomes, while homework minutes and class attendance had significant effects on treatment outcomes. This implies that MBCT is recommended to any cancer patient, if he/she is motivated to the program, regardless of their sociodemographic and clinical characteristics. Patients are encouraged to attend a standard MBCT program (eight sessions) and do the assigned homework as intensely as possible. Further studies with larger sample and objective measurements are desired.

Introduction

Psychological distress is highly prevalent in cancer patients. About one-third to one-half of cancer patients experience depression and anxiety during the course of their illness (Mitchell et al., 2011; Brandenburg et al., 2019). Psychological distress influences patients’ quality of life (Fujisawa et al., 2016), and may even affect their life prognosis (Butler et al., 2003), and thus appropriate management is important (National Comprehensive Cancer Network, 2017). Various types of interventions have been proven effective for psychological distress of cancer patients (Traeger et al., 2012; Faller et al., 2013; Kalter et al., 2018). Among them, mindfulness-based interventions (MBIs), such as mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT), have been establishing strong evidence in cancer care (Cillessen et al., 2019; Oberoi et al., 2020). They are known to improve quality of life, fatigue, sleep, stress, depression, and anxiety of cancer patients (Shneerson et al., 2013; Gotink et al., 2015; Haller et al., 2017; Zimmermann et al., 2018).

However, there are several barriers for effective delivery of MBIs for patients with cancer. Structural barriers include time constraint, financial constraint, and lack of sufficient therapist. Non-structural barriers include patients’ characteristics (such as demographic, personality, and clinical background) that impede effectiveness of MBIs (Gask, 2005; Mohr et al., 2010, 2012).
In order to efficaciously allocate limited resource to cancer patients, the identification of predictors and moderators of MBIs in cancer patients is considered useful. Past studies suggest that female patients (Nyklicek et al., 2016) and patients with higher education (Tovote et al., 2017) are more likely to benefit from MBIs. A few personality tendencies, such as higher attachment avoidance (Johannsen et al., 2017), lower extraversion (Nyklicek et al., 2016), lower conscientious, and higher neuroticism, have been suggested as predictors of effectiveness of MBIs (Jagielski et al., 2020). In a sample of patients with primary breast cancer, patients who are under radiation therapy experienced smaller effect of MBIs (Johannsen et al., 2017). Treatment adherence is another predictor for better treatment outcome (Parsons et al., 2017). Also, comorbid personality disorder is associated with poor treatment adherence, which may lead to poorer treatment outcomes (Kim et al., 2013). However, these findings derive from different patient populations and have been inconsistent.

Another direction of efficacious delivery of MBIs is to make the interventions briefer, so that larger number of patients are accessible to the intervention. In fact, several studies examined shortened versions of MBIs in cancer patients (Shaw et al., 2018). Reducing the “dosage” of MBIs reduces the burden of both the cancer patients and the therapists; however, it may also reduce the effect size of the treatment. Therefore, the identification of appropriate dosage of MBIs is necessary.

Thus, the aims of the present study are (1) to identify characteristics (predictors and moderators) of patients who benefit from MBCT for psychological distress in the scope of selectively provided MBCT to patients who are most likely to benefit from the intervention and (2) to explore the treatment reaction according to the “dosage” of MBIs and to identify the minimum number of sessions that yield significant clinical effect. We hypothesized, based on the past studies (Kim et al., 2013; Nyklicek et al., 2016; Johannsen et al., 2017; Parsons et al., 2017; Tovote et al., 2017; Jagielski et al., 2020), that patients’ age, educational history, time since cancer diagnosis, quality of life (QOL), level of psychological distress, and adherence to MBI program are significantly associated with the effectiveness of the intervention.

Methods

Study design

This study is a secondary analysis of a randomized controlled trial (RCT) of MBCT for breast cancer patients. The details of the original study are described elsewhere (Park et al., 2020). In short, 74 patients were randomized in 1:1 ratio to either eight-week MBCT or the wait-list control. The participants’ eligibility for the RCT was the following: (1) clinical diagnosis of Stage 0–III breast cancer, (2) aged between 20–74, (3) the Hospital Anxiety and Depression Scale (HADS) total score of 5 or over at recruitment, (4) the Eastern Cooperative Oncology Group performance status (ECOG) performance status of 0–2, (5) estimated prognosis of survival of 1 year or over, (6) ability to communicate in Japanese, and (7) submission of written informed consent. Exclusion criteria were the patients with (1) past experience of MBCT or MBSR, and (2) severe physical, psychiatric, or cognitive symptoms that hamper program participation. The study procedures complied with the institutional review board of Keio University School of Medicine, the Declaration of Helsinki, and the Ethics Guideline for Clinical Studies of 2009 implemented by the Japan Ministry of Health, Labour and Welfare of Japan. The study was registered in the Japanese Clinical Trial Registry (registry ID: UMIN-CTR 000016142). The results of the original study were that the MBCT group experienced significantly greater improvement at the eighth week in their psychological distress, compared with the control group (the mean difference in the HADS total score of 7.82, with 95% CI of 11.28–6.35; p < 0.001), with an effect size of Cohen’s d = 1.17. The difference remained significant at 12 weeks.

MBCT program

Our MBCT program consisted of eight 2-h sessions based on the MBCT manual by Segal et al. (2002). The program was delivered weekly in a group format with four to nine participants per group. A follow-up session was held four weeks later. The program included psychoeducation, formal and informal meditation practices, group discussion among participants, and homework that corresponded to the contents of each session. The details of the program are shown in Table 1. Based on the results of the feasibility study (Park et al., 2018), some of the content was modified to fit Japanese cancer patients (Park et al., 2020). For example, brief psychoeducation was added to the first session, and the exercise of “finding difficulties” was changed to mindfulness meditation in the fifth session. An audio CD with meditation instruction and homework checklists were handed to the participants.

Assessment

The following self-report questionnaires were administered by the participants.

The Hospital Anxiety and Depression Scale (HADS): The HADS is a 14-item self-administered questionnaire that measures severity of psychological distress (anxiety and depression) by seven items each (Zigmond and Snaith, 1983). Scores for each sub-scale range from 0 (no anxiety and/or depression) to 21 (maximum anxiety and/or depression). The higher score indicates more severe level of psychological distress.

The Functional Assessment of Cancer Therapy-General (FACT-G): The FACT-G was used to evaluate the participants’ QOL (Brady et al., 1997). This widely used questionnaire consists of 27 items, comprising four subscales: physical (score range 0–28), social/family (0–28), emotional (0–24), and functional well-being (0–28). The higher score indicates better QOL.

The Functional Assessment of Cancer Therapy-Spiritual Well-Being (FACT-Sp): The FACT-Sp is a 12-item self-administered instrument to assess spiritual well-being. The instrument comprises two subscales — one measuring a sense of meaning and peace and the other assessing the role of faith in illness (Peterman et al., 2002). The higher score indicates better spiritual well-being.

The Brief Fatigue Inventory (BFI): The BFI evaluates the participants’ fatigue (Okuyama et al., 2000). The BFI is a validated measure that consists of 10 items. The higher scores indicate more intense fatigue.

The Concerns about Recurrence Scale (CARS): The CARS evaluates the participants’ fear of cancer recurrence (FCR) (Mominno et al., 2014). The CARS has been validated in measuring FCR in patients with breast cancer. In our original study, the subscale of overall FCR (four items) was used to lessen the burden of the participants to administer. Higher scores indicate a greater level of FCR.

The Five Facet Mindfulness Questionnaire (FFMQ): The FFMQ is a 39-item self-administered questionnaire that measures five domains of mindfulness skills — observing, describing, acting
participants were absent from the eighth-week assessment. We adopted the last-observation-carried-forward (LOCF) method if by 50% or more at the eighth session from the baseline. We considered the participants as responders if their HADS total score decreased by 35% or more at the eighth session from the baseline (Akizuki et al., 2003). The definition of the remitter was the participants whose HADS total score after the intervention (eighth week) was 10 or lower. This is based on the past studies that demonstrated that the HADS total score of 10/11 was an optimal cutoff score for screening cancer patients with high psychological distress (adjustment disorder or major depressive disorder) (Akizuki et al., 2003). The definition of the remitter was based on the past studies that demonstrated their possible association with treatment response (Johannsen et al., 2017; Parsons et al., 2017; Toyote et al., 2017), and based on our hypotheses that patients who are at medically stable conditions (with longer time since diagnosis and better QOL) are more likely to benefit from MBIs. Considering high collinearity (r=0.691, p<0.001), we chose the number of class attendance instead of minutes spent for homework for logistic regression analysis to represent treatment adherence.

The participants also reported time spent on the homework during the previous week of the session. Sociodemographic and clinical data were collected from the electronic health record.

### Definition of remitter and responder

We divided the participants into remitters and non-remitters, and responders and non-responders. The definition of the remitter was the participants whose HADS total score after the intervention (eighth week) was 10 or lower. This is based on the past study that demonstrated that the HADS total score of 10/11 was an optimal cutoff score for screening cancer patients with high psychological distress (adjustment disorder or major depressive disorder) (Akizuki et al., 2003). The definition of the responder was the participants whose HADS total score reduced by 50% or more at the eighth session from the baseline. We adopted the last-observation-carried-forward (LOCF) method if participants were absent from the eighth-week assessment.

### Statistical analysis

To examine the factors associated with treatment response and remission, we conducted bivariate analysis using the chi-square test for categorical variables, t-tests for normally distributed continuous variables, and the Wilcoxon rank sum tests for continuous variables with skewed distribution. Then, we entered the following variables into logistic regression analysis: age, history of education, time since diagnosis, QOL, HADS total score at baseline, and treatment adherence. These variables were selected based on the past studies that demonstrated their possible association with treatment response (Johannsen et al., 2017; Parsons et al., 2017; Toyote et al., 2017), and based on our hypotheses that patients who are at medically stable conditions (with longer time since diagnosis and better QOL) are more likely to benefit from MBIs. Considering high collinearity (r=0.691, p<0.001), we chose the number of class attendance instead of minutes spent for homework for logistic regression analysis to represent treatment adherence.

To estimate optimal dosage of MBCT, we performed generalized estimating equations (GEE) using a model with logit link and binominal distribution to examine when patients start to respond or reach remission over time. The working correlation matrix was specified to be compound symmetry. The significance levels for all the tests were two-sided at 5%. All the statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA) and IBM SPSS Statistics version 24.0.0.0.

### Table 1. MBCT program components

| Session | Theme                  | Contents                                                                 | Homework                                                                 |
|---------|------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| 1       | Overview of mindfulness | Psychoeducation: psychological reactions of patients with cancer/what is mindfulness Exercise: Mindfulness eating (raisin exercise)/body scan | Mindfulness eating: at least one time a day Body scan (10 min): more than one time, everyday |
| 2       | Facing difficulties    | Psychoeducation: association of mood and thoughts Exercise: body scan/mindful breathing meditation | Body scan (15 min): at least one time a day Mindful breathing meditation (10 min): at least one time a day Pleasant activity and event record: at least one thing, everyday |
| 3       | Mindful breathing      | Psychoeducation: pleasant activities and events Exercise: mindfulness meditation/gentle yoga/mindful walking | Mindfulness meditation (15 min): at least one time a day Gentle yoga (10 min): at least one time a day Mindful walking: optional |
| 4       | Staying present        | Psychoeducation: reactions to pleasant and unpleasant events Exercise: mindfulness meditations | Mindfulness meditations (25 min): at least one time a day Three-minute breathing space exercise: three times a day |
| 5       | Allowing (letting it be)| Psychoeducation: compassion (appreciation and gratitude in life) Exercise: mindfulness meditation/compassion meditation (loving and kindness) | Building pleasant habits Record of appreciation and gratitude Mindfulness meditations (30 min): at least one time a day |
| 6       | Thoughts are not facts | Psychoeducation: cognitive biases Exercise: mindfulness meditations/compassion meditation | Record of appreciation and gratitude Mindfulness meditations (30 min): at least one time a day |
| 7       | Taking care of yourself| Psychoeducation: choosing functional behaviors/behavioral activation/identifying triggers Exercise: mindfulness meditations/compassion meditation | Responses to triggers Record of appreciation and gratitude Mindfulness meditations (30 min): at least one time a day |
| 8       | Dealing with future struggles | Review of and course/personal reflections of course/plans for future practice/farewell Exercise: body scan/mindfulness meditations | Mindfulness meditations (25 min): at least one time a day Three-minute breathing space exercise: three times a day |

With awareness, non-judging of inner experience, and non-reacting with inner experience (Baer et al., 2008). The higher score indicates a greater level of mindfulness tendency. This scale was used as a process measure of the intervention — to measure whether the participants has taken up mindfulness skills.

The primary outcome was the HADS and was administered at baseline (pretreatment), after the intervention (eighth week), and at the end of each session. Other questionnaires were administered at baseline and after the intervention (eighth week).

The participants also reported time spent on the homework during the previous week of the session. Sociodemographic and clinical data were collected from the electronic health record.
**Table 2. Sociodemographic and clinical characteristics of the participants**

| Sociodemographic backgrounds | n (%) |
|------------------------------|-------|
| Age (years); mean (SD)       | 53.69 (8.8) |
| Cohabiting                   | 61 (82.4) |
| Married                      | 53 (71.6) |
| Not-married                  | 21 (28.4) |
| Employed                     | 35 (47.3) |
| Not-employed                 | 39 (53.0) |
| Caregiving                   | 15 (20.3) |
| Education                    | 36 (48.6) |
| Cancer stage                 | 30 (40.5) |
| Time since diagnosis         | 29 (39.2) |
| Five years or more           | 3 (4.1) |
| Recent received treatment (within 1 month of beginning of MBCT program) | 18 (24.3) |
| Chemotherapy                 | 9 (12.2) |
| Radiation therapy            | 5 (6.8) |
| Hormonal therapy             | 42 (56.8) |
| Herceptin                    | 5 (6.8) |
| History of psychiatric care  | 16 (21.6) |

Data are presented as n (%) unless indicated otherwise. MBCT, mindful-based cognitive therapy; SD, standard deviation.

**Results**

**Patient characteristics**

The participants’ characteristics are shown in Table 2. The mean age of the participants was 53.69 (SD = 8.79). All of them were female. Approximately one third of them were within 1 year since diagnosis, and one fourth were over 5 years. The participants who received chemotherapy, radiation therapy, and hormonal-therapy within 1 month before the program began were 12.2% (n = 9), 6.8% (n = 5), and 43.2% (n = 32), respectively.

**Bivariate analyses**

The results of the bivariate analyses are shown in Table 3. There was no significant difference in any of the sociodemographic and clinical variables. Patients who reached remission had lower levels of anxiety, depression, recurrent anxiety, sense of fatigue, and better QOL at baseline. Patients who responded to MBCT had better QOL compared with non-responder at baseline. Mindfulness tendency (the total score of FFMQ) was not significant. The participants who attended the program more frequently and who did their homework more intensely were more likely to experience remission and better treatment response.

**Multivariate analysis**

The results of multivariate analyses are shown in Table 4. The HADS total score at baseline and class attendance were significant predictor for remission (HADS total score; odds ratio (OR) = 0.84, p < 0.01 [95% confidence interval (95% CI), 0.76–0.92], and class attendance; OR = 1.91, p < 0.01 [95% CI, 1.26–2.89]). Only the class attendance remained significant as a predictor for treatment response (OR = 1.71, p < 0.05 [95% CI, 1.12–2.63]).

**Initial treatment reaction**

Proportions of patients who reached remission and response at each session are shown in Table 5. More than 50% of patients remitted at the seventh session. The significant difference in the treatment response was observed at the seventh session.

**Discussion**

The aim of this study was to identify the characteristics of patients who benefit from MBCT and explore the initial treatment reactions to seek the optimal number of sessions that produce significant effects.

There was no significant difference in the sociodemographic and clinical backgrounds between the patients who did and did not experience either remission or response. The patients with lower level of psychological distress at the baseline were more likely to experience remission. The better program adherence had a positive influence on both remission and response. Concerning the initial treatment reaction, 50% of the participants reached remission at the seventh session and there was significant difference in treatment response at the seventh session.

Past studies on MBIs have identified no definite sociodemographic predictors for treatment outcomes of MBIs, except that female gender is a predictor for better treatment outcome (Nyklicek et al., 2016). In a comparative study of MBCT and cognitive behavioral therapy (CBT) for depressive symptoms in patients with diabetes, patients with higher educational history were more likely to benefit from MBCT compared with CBT. However, influence of educational history was not significant in a within-group analysis of MBCT (Nyklicek et al., 2016). The current study yielded similar findings that educational history did not influence the effectiveness of MBCT.

In the current study, lower levels of psychological distress at baseline served as a predictor for remission but not for treatment response. While some of the past studies indicated that lower levels of psychological distress at baseline predicted better treatment response (Trompetter et al., 2016), the majority of the past studies denied significant association between the levels of psychological distress at baseline and treatment response (Gilpin et al., 2017; Johanssen et al., 2017; Tovote et al., 2017). In contrast, a systematic review on the association of patients’ mindfulness practice and treatment outcome demonstrated that better adherence to the treatment, which is represented as time spent on homework, consistently predicts better treatment outcome (Parsons et al., 2017). The current study was consistent
### Table 3. Results of the bivariate analyses

|                          | Remitter n = 49 | Non-remitter n = 25 | p*     | Responder n = 35 | Non-responder n = 39 | p*     |
|--------------------------|-----------------|---------------------|--------|------------------|----------------------|--------|
| **Sociodemographic backgrounds, N (%)** |                  |                     |        |                  |                      |        |
| Age (years) ± mean (SD)  | 53.67 ± 8.9     | 53.72 ± 8.8         | 0.98   | 53.00 ± 8.9      | 54.31 ± 8.8          | 0.53   |
| Cohabiting               | 41 (83.7)       | 20 (80.0)           | 0.69   | 29 (82.9)        | 32 (82.1)            | 0.93   |
| Married                  | 37 (75.5)       | 16 (64.0)           | 0.34   | 26 (74.3)        | 27 (69.2)            | 0.38   |
| Not-married              | 12 (24.5)       | 9 (36.0)            |        | 9 (25.7)         | 12 (30.8)            |        |
| Employed                 | 24 (49.0)       | 11 (44.0)           | 0.22   | 17 (48.6)        | 18 (46.2)            | 0.50   |
| Not-employed             | 25 (51.0)       | 14 (56.0)           |        | 18 (51.4)        | 21 (53.8)            |        |
| Caregiving               | 7 (14.3)        | 8 (32.0)            | 0.07   | 7 (20.0)         | 8 (20.5)             | 0.96   |
| **Education**            |                  |                     |        |                  |                      |        |
| 12 years or less         | 6 (12.2)        | 2 (8.0)             | 0.38   | 3 (8.6)          | 5 (12.8)             | 0.82   |
| 13–15 years              | 22 (44.9)       | 8 (32.0)            |        | 15 (42.9)        | 15 (38.5)            |        |
| 16 years or more         | 21 (42.9)       | 15 (60.0)           |        | 17 (48.6)        | 19 (48.7)            |        |
| **Clinical backgrounds, N (%)** |                  |                     |        |                  |                      |        |
| Cancer stage             |                  |                     |        |                  |                      |        |
| 0                        | 11 (22.4)       | 4 (16.0)            | 0.73   | 7 (20.0)         | 8 (20.5)             | 0.91   |
| I                        | 19 (38.8)       | 8 (32.0)            | 12 (34.3) | 15 (38.5)   |                      |        |
| II                       | 17 (34.7)       | 12 (48.0)           | 14 (40.0) | 15 (38.5)   |                      |        |
| III                      | 2 (4.1)         | 1 (4.0)             |        | 2 (5.7)         | 1 (2.6)              |        |
| Time since diagnosis     |                  |                     |        |                  |                      |        |
| Less than 1 year         | 11 (22.4)       | 14 (56.0)           | 0.98   | 11 (31.4)       | 14 (35.9)            | 0.92   |
| Less than 5 years        | 13 (26.5)       | 18 (72.0)           |        | 15 (42.9)       | 16 (41.0)            |        |
| Five years or more       | 8 (16.3)        | 10 (40.0)           |        | 9 (25.7)        | 9 (23.1)             |        |
| Recent received treatment (within 1 month of beginning of MBCT program) | | | | | | |
| Chemotherapy             | 3 (6.1)         | 6 (24.0)            | 0.52   | 4 (11.4)         | 5 (12.8)             | 0.86   |
| Radiation therapy        | 2 (4.1)         | 3 (12.0)            | 0.88   | 3 (8.6)          | 2 (5.1)              | 0.56   |
| Hormonal therapy         | 20 (40.8)       | 22 (88.0)           | 0.38   | 23 (65.7)       | 19 (48.7)            | 0.14   |
| Herceptin                | 3 (6.1)         | 2 (8.0)             | 0.43   | 3 (8.6)          | 2 (5.1)              | 0.56   |
| History of psychiatric care | 9 (18.4)   | 7 (28.0)            | 0.37   | 8 (22.9)         | 8 (20.5)             | 0.85   |
| **Psychological backgrounds (mean ± SD)** |                  |                     |        |                  |                      |        |
| HADS                     |                  |                     |        |                  |                      |        |
| Total                    | 12.61 ± 7.4     | 19.00 ± 5.0         | <0.001 | 15.86 ± 8.2     | 13.79 ± 6.4          | 0.23   |
| Anxiety                  | 6.71 ± 3.6      | 9.00 ± 3.3          | 0.009  | 8.11 ± 4.3      | 6.92 ± 3.0           | 0.16   |
| Depression               | 5.90 ± 4.2      | 10.00 ± 3.1         | <0.001 | 7.74 ± 4.3      | 6.87 ± 4.3           | 0.39   |
| FACT-G                   |                  |                     |        |                  |                      |        |
| Total                    | 66.96 ± 14.2    | 51.30 ± 10.5        | <0.001 | 63.24 ± 14.9    | 60.26 ± 15.1         | 0.76   |
| Physical                 | 13.73 ± 9.1     | 12.75 ± 7.8         | 0.65   | 15.62 ± 8.2     | 11.41 ± 8.6          | 0.035  |
| Social/family            | 18.71 ± 6.3     | 12.95 ± 6.6         | <0.001 | 16.84 ± 6.3     | 16.70 ± 7.5          | 0.93   |
| Emotional                | 16.08 ± 4.5     | 12.20 ± 3.4         | <0.001 | 14.46 ± 4.7     | 15.05 ± 4.4          | 0.58   |
| Functional well-being    | 18.43 ± 5.6     | 13.40 ± 5.3         | <0.001 | 16.31 ± 5.6     | 17.10 ± 6.3          | 0.57   |
| FASTIT_Sp                | 25.94 ± 8.7     | 17.72 ± 6.5         | <0.001 | 22.2 ± 8.5      | 23.97 ± 9.3          | 0.41   |
| CARS                     | 13.08 ± 5.2     | 13.76 ± 4.7         | 0.58   | 13.77 ± 5.8     | 12.90 ± 4.2          | 0.46   |

(Continued)
with those results. Homework is an important component of psychotherapy that brings its effect to the real world (Addis and Jacobson, 2000). Those who do their homework properly have been shown to gain better effect in treatment than otherwise (Burns and Spangler, 2000; Kazantzis et al., 2000, 2001; Kazantzis and Lampropoulos, 2002). In MBIs, the past studies showed that time spent on meditation affects brain changes (Ricard et al., 2014; Kral et al., 2018). It has also been suggested that meditating more time was associated with improved meditation quality and that improved meditation quality functioned as a mechanism linking meditation practice time and psychological outcomes (Goldberg et al., 2020).

Systematic reviews demonstrated that shortened MBI programs yields smaller effect size than standard MBIs (Creswell, 2017; Shaw et al., 2018; Cillessen et al., 2019). In the current study, it was not until seventh session that statistically significant improvement in the patients’ psychological distress was observed. Also, it was not until seventh session that more than half of the participants achieved remission. The standard dosage of MBCT (eighth sessions) seems desirable to attain clinically significant effect.

The current study indicated that simply making the MBCT shorter would not yield clinically significant effects on patients with cancer. The number of class attendance was also a significant factor in remission and treatment response. Since MBIs include meditation and various other elements (Britton et al., 2018), dismantling studies to examine active ingredients may be meaningful in the field of oncology.

There was some anecdotal evidence that doing homework and class attendance contributed to the improvement in the participants’ wellbeing. The following are some excerpts from the participants’ comments at the end of the program:

“I was able to understand it little by little because of the homework.”

“At first, the homework was a real hassle. But I managed to do it because I felt good when I did it.”

“Meditations helped relaxing my mind and body. As I continued to meditate, I felt more comfortable.”

“I could feel my own mind changing with each session.”

Table 3. (Continued.)

|                        | Remitter n = 49 | Non-remitter n = 25 | p* | Remitter n = 35 | Non-remitter n = 39 | p* |
|------------------------|-----------------|---------------------|----|-----------------|---------------------|----|
| BFI                    |                 |                     |    |                 |                     |    |
| Total                  | 24.8 ± 20.0     | 39.12 ± 19.6        | 0.004 | 27.09 ± 19.9 | 31.92 ± 21.7 | 0.32 |
| Average                | 2.73 ± 2.2      | 4.35 ± 2.2          | 0.004 | 3.01 ± 2.2   | 3.55 ± 2.4   | 0.32 |
| FFMQ                   |                 |                     |    |                 |                     |    |
| Total                  | 117.24 ± 14.3   | 115.60 ± 12.7       | 0.63 | 115.83 ± 15.3 | 117.46 ± 12.2 | 0.61 |
| Observing              | 24.14 ± 3.5     | 23.60 ± 4.0         | 0.55 | 23.97 ± 3.3   | 23.95 ± 4.0   | 0.98 |
| Non-reaction           | 20.69 ± 3.5     | 20.44 ± 2.9         | 0.75 | 20.37 ± 3.6   | 20.82 ± 2.9   | 0.56 |
| Non-judging            | 23.22 ± 3.4     | 22.88 ± 3.7         | 0.69 | 23.49 ± 3.6   | 22.77 ± 3.5   | 0.39 |
| Describing             | 23.78 ± 3.4     | 23.76 ± 2.5         | 0.98 | 23.09 ± 3.8   | 24.38 ± 2.2   | 0.08 |
| Awareness              | 25.41 ± 3.9     | 24.92 ± 3.6         | 0.62 | 24.91 ± 4.0   | 25.54 ± 3.6   | 0.48 |

| Treatment adherence (mean ± SD) |                 |                     |    |                 |                     |    |
| Class attendance          | 6.98 ± 1.2      | 5.40 ± 2.6          | <0.001 | 7.14 ± 1.0   | 5.82 ± 2.3   | 0.002 |
| Total home practice time (min) | 1257.05 ± 616.3 | 795.14 ± 565.9      | 0.003 | 1289.44 ± 634.6 | 939.29 ± 594.5 | 0.02 |

HADS, Hospital Anxiety and Depression Scale; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT-Sp, Functional Assessment of Chronic Illness Therapy-Spiritual; CARS, Concerns about Recurrence Change; BFI, Brief Fatigue Inventory; FFMQ, Five Facet Mindfulness Questionnaire.

*p: significance level. 95% confidence interval, both side.

Table 4. Results of multivariate analysis

|                      | Remission |                      | Response |                      |
|----------------------|-----------|----------------------|----------|----------------------|
|                      | Odds ratio | 95% CI | p   | Odds ratio | 95% CI | p   |
| Age                  | 0.95      | 0.87–1.03 | 0.18 | 0.98      | 0.92–1.05 | 0.64 |
| Education            | 0.53      | 0.17–1.62 | 0.26 | 1.05      | 0.46–2.43 | 0.90 |
| Time since diagnosis | 0.90      | 0.39–2.05 | 0.80 | 0.97      | 0.48–1.94 | 0.92 |
| FACT-G Physical      | 1.01      | 0.93–1.10 | 0.81 | 1.05      | 0.99–1.12 | 0.12 |
| HADS_Total           | 0.84      | 0.76–0.92 | <0.001 | 1.03      | 0.96–1.11 | 0.36 |
| Class attendance     | 1.90      | 1.25–2.89 | 0.003 | 1.72      | 1.12–2.65 | 0.013 |

FACT-G, Functional Assessment of Cancer Therapy-General; HADS, Hospital Anxiety and Depression Scale.
Clinical implications

In our study sample, sociodemographic and clinical characteristics did not significantly influence the treatment outcomes, while homework minutes and class attendance had significant effects on treatment outcomes. This implies that MBCT is recommended to any cancer patient, if he/she is motivated to the program, regardless of their sociodemographic and clinical characteristics. Patients are encouraged to attend a standard MBCT program, and do the assigned homework as intensely as possible.

Since it was not until seventh session that more than half of the participants achieved remission. The standard dosage of MBCT (eight sessions) seems desirable to attain clinically significant effect.

Limitations

The current study has some limitations. First, the study was a single-center study with relatively small number of participants. The patients with advanced cancer were excluded. Thus, its generalizability is limited. Also, due to sample size, we were not able to examine the influence of patients’ clinical background and the severity of psychological distress on the number of sessions that are needed to attain remission. Second, all the assessments were self-reported, thus lacks objectivity. Third, substantial proportion of the participants corresponded to remitters, since we defined remission with the HADS score of 10/11, while we screened potential participants with the HADS score of 5/6. Fourth, we did not examine personality characteristics, although they have been identified as predictors in two studies that addressed cancer patients (Johannsen et al., 2017; Jagielski et al., 2020). This is because our study had been conducted before these findings came out. Fifth, we were not able to examine the influence of radiation therapy, which had been shown to associate with patients’ adherence to MBCT (Johannsen et al., 2017), due to small number of participants. Finally, since our study employed wait-list control and did not adopt psychological placebo, we cannot exclude the influence of nonspecific effect of group psychotherapy.

Despite these limitations, the current study provides some suggestions on implication of MBCT for patients with cancer. Furthermore, multi-center study with larger study sample and objective measurement is warranted.

Acknowledgments. The authors thank Dr Teppei Kosugi, Dr Atsuo Nakagawa, Dr Maiko Takahashi, and Dr Tetsu Hayashida for their support to the implementation of the study.

Author contributions. D.F. conceived and designed the study, S.P. and N.T. collected the data. Y.S. and N.T. analyzed the data. N.T. and D.F. have full access to all of the data, and N.T. and D.F. take responsibility for the integrity of the data and the accuracy of the analysis. N.T. drafted the manuscript. M.S., A.N., D.F., and S.P. drafted the grant proposal. Y.S., Y.T., M.M., and all other authors critically reviewed the manuscript for content and approved the final version.

Funding. This work was supported by JSPS KAKENHI (Grant-in-Aid for Scientific Research; Grant Nos JP15K09875 and JP18K07476), Keio Gijyuku Academic Development Funds, and AMED under Grant No. JP20Ik0310059.

Conflict of interest. All authors except M.M. have no conflicts of interest. M.M. has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past 3 years. The other authors have no potential conflicts of interest to disclose.

References

Addis ME and Jacobson NS (2000) A closer look at the treatment rationale and homework compliance in cognitive-behavioral therapy for depression. Cognitive Therapy and Research 24, 313–326.

Akiuzki N, Akechi T, Nakanishi E, et al., (2003) Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. Cancer Care 28(3), 259–261.

Baer RA, Smith GT, Lykins E, et al., (2008) Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. Assessment 15(3), 329–342.

Brady MJ, Cella DF, Mo F, et al., (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. Journal of Clinical Oncology 15(3), 974–986.

Brandenbarg D, Maass SWMC, Geurse OP, et al., (2019) A systematic review on the prevalence of symptoms of depression, anxiety and distress in long-term cancer survivors: Implications for primary care. European Journal of Cancer Care 28(3), e13086.

Britton WB, Davis JH, Loucks EB, et al., (2018) Dismantling mindfulness-based cognitive therapy: Creation and validation of 8-week focused attention and open monitoring interventions within a 3-armed randomized controlled trial. Behaviour Research and Therapy 101, 92–107.

Burns DD and Spangler DL (2000) Does psychotherapy homework lead to improvements in depression in cognitive-behavioral therapy or does improvement lead to increased homework compliance? Journal of Consulting and Clinical Psychology 68(1), 46–56.

Butler LD, Koopman C, Cordova MJ, et al., (2003) Psychological distress and pain significantly increase before death in metastatic breast cancer patients. Psychosomatic Medicine 65(3), 416–426.

Table 5. Results of initial treatment reaction

| Number of sessions | Remission rate (%) | 95% CI | Odds ratio | 95% CI |
|--------------------|--------------------|-------|------------|-------|
| Remission          |                    |       |            |       |
| 0                  | 30.0               | 0.19–0.40 | reference |
| 1                  | 36.0               | 0.25–0.47 | 1.33      | 0.88–2.00 |
| 2                  | 39.0               | 0.28–0.51 | 1.52      | 1.01–2.29 |
| 3                  | 42.0               | 0.31–0.54 | 1.73      | 1.15–2.61 |
| 4                  | 41.9               | 0.30–0.54 | 1.71      | 1.13–2.57 |
| 5                  | 44.9               | 0.33–0.57 | 1.93      | 1.28–2.91 |
| 6                  | 47.1               | 0.35–0.59 | 2.10      | 1.36–3.25 |
| 7                  | 56.8               | 0.45–0.69 | 3.11      | 2.03–4.76 |
| 8                  | 66.2               | 0.55–0.77 | 4.63      | 3.08–6.96 |
| Response           |                    |       |            |       |
| 1                  | 18.7               | 0.99–0.28 | reference |
| 2                  | 11.1               | 0.04–0.19 | 0.54      | 0.25–1.19 |
| 3                  | 16.5               | 0.08–0.26 | 0.86      | 0.42–1.77 |
| 4                  | 19.2               | 0.10–0.29 | 1.04      | 0.52–2.07 |
| 5                  | 24.1               | 0.14–0.35 | 1.39      | 0.71–2.71 |
| 6                  | 25.3               | 0.14–0.37 | 1.48      | 0.73–2.98 |
| 7                  | 31.7               | 0.20–0.43 | 2.02      | 1.04–3.93 |
| 8                  | 47.3               | 0.36–0.59 | 3.91      | 2.10–7.28 |
Cillessen L, Johannsen M, Speckens AEM, et al. (2019) Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials. Psychooncology 28(12), 2257–2269.

Creswell JD (2017) Mindfulness interventions. Annual Review of Psychology 68, 491–516.

Faller H, Schuler M, Richard M, et al. (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: Systematic review and meta-analysis. Journal of Clinical Oncology 31(6), 782–793.

Fujisawa D, Inoguchi H, Shimoda H, et al. (2016) Impact of depression on health utility value in cancer patients. Psychooncology 25(5), 491–495.

Gask L (2005) Overt and covert barriers to the integration of primary and specialist mental health care. Social Science & Medicine 61(8), 1785–1794.

Gilpin HR, Keyes A, Stahl DR, et al. (2016) Predictors of treatment outcome in contextual cognitive and behavioral therapies for chronic pain: A systematic review. Journal of Pain 18(10), 1153–1164.

Goldberg SB, Knoeppel C, Davidson RJ, et al. (2020) Does practice quality mediate the relationship between practice time and outcome in mindfulness-based stress reduction? Journal of Counseling Psychology 67(1), 115–122.

Gotink RA, Chu P, Busschbach JJ, et al. (2015) Standardised mindfulness-based interventions in healthcare: An overview of systematic reviews and meta-analyses of RCTs. PLoS One 10(4), e0124344.

Haller H, Winkler MM, Klose P, et al. (2017) Mindfulness-based interventions for women with breast cancer: An updated systematic review and meta-analysis. Acta Oncologica 56(12), 1665–1676.

Jaglielski CH, Tucker DC, Dalton SO, et al. (2020) Personality as a predictor of well-being in a randomized trial of a mindfulness-based stress reduction of Danish women with breast cancer. Journal of Psychosocial Oncology 38 (1), 4–19.

Johannsen M, O’Toole MS, O’Connor M, et al. (2017) Clinical and psychological moderators of the effect of mindfulness-based cognitive therapy on persistent pain in women treated for primary breast cancer — explorative analyses from a randomized controlled trial. Acta Oncologica 56(2), 321–328.

Kalter J, Verdonck-de Leeuw IM, Sweegers MG, et al. (2018) Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs. Psychooncology 27(4), 1150–1161.

Kazantzis N and Lampropoulos GK (2002) Reflecting on homework in psychotherapy: What can we conclude from research and experience? Journal of Clinical Psychology 58(5), 577–585.

Kazantzis N, Deane FP and Ronan KR (2000) Homework assignments in cognitive and behavioral therapy: A meta-analysis. Clinical Psychology: Science and Practice 7(2), 189–202.

Kazantzis N, Ronan KR and Deane FP (2001) Concluding causation from correlation: Comment on burns and Spangler (2000). Journal of Consulting and Clinical Psychology 69(6), 1079–1083. discussion 84–6.

Kim B, Cho SJ, Lee KS, et al. (2013) Factors associated with treatment outcomes in mindfulness-based cognitive therapy for panic disorder. Yonsei Medical Journal 54(6), 1454–1462.

Kral TRA, Schuyler BS, Mumford JA, et al. (2018) Impact of short- and long-term mindfulness meditation training on amygdala reactivity to emotional stimuli. NeuroImage 181, 301–313.

Mitchell AJ, Chan M, Bhatti H, et al. (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncology 12(2), 160–174.

Mohr DC, Ho J, Duffey J, et al. (2010) Perceived barriers to psychological treatments and their relationship to depression. Journal of Clinical Psychology 66(4), 394–409.

Mohr DC, Ho J, Duffey J, et al. (2012) Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: A randomized trial. JAMA 307(21), 2278–2285.

Momoko K, Akechi T, Yamashita T, et al. (2014) Psychometric properties of the Japanese version of the concerns about recurrence scale (CARS-J). Japanese Journal of Clinical Oncology 44(5), 456–462.

National Comprehensive Cancer Network (2017) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Distress Management. NCCN Distress guideline 2017 ver.2.

Nyklíček I, van Son J, Pop VJ, et al. (2016) Does mindfulness-based cognitive therapy benefit all people with diabetes and comorbid emotional complaints equally? Moderators in the DiaMind trial. Journal of Psychosomatic Research 91, 40–47.

Oberoi S, Yang J, Woodgate RL, et al. (2020) Association of mindfulness-based interventions with anxiety severity in adults with cancer: A systematic review and meta-analysis. JAMA Network Open 3(8), e2012598.

Okuyama T, Akechi T, Kugaya A, et al. (2000) Development and validation of the cancer fatigue scale: A brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. Journal of Pain and Symptom Management 19(1), 5–14.

Park S, Sado M, Fujisawa D, et al. (2018) Mindfulness-based cognitive therapy for Japanese breast cancer patients – a feasibility study. Japanese Journal of Clinical Oncology 48(1), 68–74.

Park S, Sato Y, Takita Y, et al. (2020) Mindfulness-based cognitive therapy for psychological distress, fear of cancer recurrence, fatigue, spiritual well-being, and quality of life in patients with breast cancer – A randomized controlled trial. Journal of Pain and Symptom Management 60(2), 381–389.

Parsons CE, Crane C, Parsons LJ, et al. (2017) ‘Home practice in mindfulness-based cognitive therapy and mindfulness-based stress reduction: A systematic review and meta-analysis of participants’ mindfulness practice and its association with outcomes’. Behaviour Research and Therapy 95, 29–41.

Peterman AH, Fitchett G, Brady MJ, et al. (2002) Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy scale (FACIT-Sp). Annals of Behavioral Medicine 24(1), 49–58.

Ricard M, Lutz A and Davidson RJ (2014) Mind of the meditator. Scientific America 311, 38–45.

Segal ZV, Williams JMG and Teasdale JD (2002) Mindfulness-based Cognitive Therapy for Depression: A new Approach to Preventing Relapse. New York, NY, USA: Guildford Press.

Shaw JM, Sekelja N, Frasca D, et al. (2018) Being mindful of mindfulness interventions in cancer: A systematic review of intervention reporting and study methodology. Psycho-Oncology 27(4), 1162–1171.

Sheenerson C, Taskila T, Gale N, et al. (2013) The effect of complementary and alternative medicine on the quality of life of cancer survivors: A systematic review and meta-analyses. Complementary Therapy in Medicine 21(4), 417–429.

Tovote KA, Schroeners MJ, Snipe E, et al. (2017) What works best for whom? Cognitive behavior therapy and mindfulness-based cognitive therapy for depressive symptoms in patients with diabetes. PLoS One 12(6), e0179941.

Traeger L, Greer JA, Fernandez-Robles C, et al. (2012) Evidence-based treatment of anxiety in patients with cancer. Journal of Clinical Oncology 30(11), 1197–1205.

Trompeter RH, Bohlmeyer ET, Lamers SM, et al. (2016) Positive psychological well-being Is required for online self-help acceptance and commitment therapy for chronic pain to be effective. Frontiers in Psychology 7, 353.

Zigmond AS and Snaith RP (1983) The hospital anxiety and depression scale. JAMA Network Open.